Related Experiment Video

Updated: Jul 22, 2025

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.5K

Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

M A Gouda1, M I Hu2, M E Cabanillas2

  • 1Departments of Investigational Cancer Therapeutics.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|July 20, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

2.9K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.7K

Related Experiment Videos

Last Updated: Jul 22, 2025

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.5K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

2.9K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K

Articles linked to this work by shared authors, journal, and citation graph.

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02.

ESMO open·2026

ESMO basic requirements for AI-based biomarkers in oncology (EBAI).

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations.

ESMO open·2025

Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.

ESMO open·2025

Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET.

ESMO open·2025

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Thymic radiation is associated with worse outcomes in patients with NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us